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Abstract To assess anti-tumor activity of sequential
epirubicin/cyclophosphamide followed by docetaxel with
the randomized addition of celecoxib in HER2 negative
patients or trastuzumab in HER2 positive patients. From
May 2004 till October 2007, 340 patients with stage II
and III breast adenocarcinoma, ineligible for breast con-
serving surgery, received eight sequential three weekly
cycles of EC-D [epirubicin (75 mg/m2)–cyclophosphamide
(750 mg/m2) for four cycles followed by docetaxel
(100 mg/m2) for four cycles]. HER2-negative patients
(N = 220) were randomized to receive concomitantly with
docetaxel celecoxib 800 mg/day during cycles 5–8 or no
additional treatment, while HER2-positive patients con-
firmed by FISH (N = 120) were randomized to trast-
uzumab concomitant to docetaxel (8 mg/kg then 6 mg/kg
IV every 3 weeks) or no additional preoperative treatment.
In the HER2 negative group, pCR (grade 1 and 2 of Che-
vallier’s classification) was observed in 11.5 and 13% of
patients treated without and with neoadjuvant Celecoxib,
respectively. In the HER2 positive group, pCR rate reached
26% in those who received neoadjuvant trastuzumab versus
19% in the others. There was no unexpected toxicity, no
cardiac toxicity, and no toxic death. Triple negative breast
cancers experience the highest pCR rate of 30%. Celecoxib
is not likely to improve pCR rates in addition to EC-D in
patients with HER2-negative tumor. In HER2-positive
tumor patients, trastuzumab added to ECD leads to
increased pCR rates. It was the only combination to
deserve further study according to the two-stage Fleming’s
design used in this trial.
Keywords Breast cancer  Neoadjuvant chemotherapy 
Trastuzumab  Celecoxib
Introduction
Preoperative systemic therapy is now an established part of
the management of large, potentially operable, and locally
advanced breast cancers as it could achieve down-staging
of the primary tumor, thereby allowing breast-conserving
surgery [1–4]. Neoadjuvant therapy has been shown to be
equivalent to adjuvant therapy in terms of survival and
relapse-free survival [5]. The achievement of pathological
complete response (pCR) including nodal involvement
could be a surrogate marker to predict long-term outcome
and is currently the main endpoint reported by neoadjuvant
chemotherapy protocols [6–9]. Clinical trials in this setting
therefore require fewer patients and can be completed more
rapidly. However, not all patients achieving pCR will be
cured and other surrogate markers must therefore be
identified [10, 11].
Cyclooxygenase-2 (COX2), which mediates the pro-
duction of prostaglandins and thromboxanes from
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arachidonic acid, is induced in inflammation and in cancer
development and progression [12–15]. COX-2 is frequently
over-expressed in breast cancer, and associated with
unfavorable outcomes. Over-expression of COX2 in breast
cancer cell lines increases cell migration and invasion [16].
Celecoxib is a COX-2 inhibitor with anti-angiogenic and
pro-apoptotic activity. In breast cancer cells celecoxib
analogs were shown to be potent inhibitors of phospho-
Akt-signaling pathways and to induce apoptosis [17]. In
animal models, treatment with selective COX-2 inhibitors
reduced the formation, growth, microvasculature, and
metastases of tumors [13].
Trastuzumab, a recombinant humanized monoclonal
antibody targeting the HER2 receptor, is clinically active in
HER2 metastatic breast cancer when used alone or in
combination with chemotherapy [18]. Large trials have
established a survival benefit for trastuzumab in the adju-
vant setting [19, 20]. A limited number of phase II trials
have evaluated trastuzumab in combination with various
chemotherapeutic agents in the neoadjuvant setting [2, 21–
24]. In these studies, the pCR rates obtained ranged from
12 to 47% [23]. Three randomized clinical trials have
studied the combination of trastuzumab with a sequential
regimen of anthracyclines-based chemotherapy then pac-
litaxel or docetaxel. In the M.D. Anderson group trial, the
pCR rate was 25% in the chemotherapy-only arm versus
67% in the trastuzumab arm [25, 26]. In the NOAH trial
reported by Gianni et al. [27], the pCR rates were,
respectively, 23% versus 43% (P = 0.002) without or with
trastuzumab. In the GeparQuattro, including 453 HER2
positive patients, pCR rates were, respectively, 20 and
41.3% without or with trastuzumab [28].
The aim of the present randomized phase II study was to
assess anti-tumor activity of sequential epirubicin/cyclo-
phosphamide followed by docetaxel with the randomized
addition of celecoxib in HER2 negative tumor patients or
trastuzumab in HER2 positive tumor patients in terms of
pathological complete response.
Patients and methods
Patients and chemotherapy regimen
The randomized phase II Remagus 02 trial included
patients from four different institutions. Eligibility criteria
for the study were female patients over the age of 18 and
under the age of 65 with histologically proven non-meta-
static invasive breast carcinoma (Stage II and III), not
amenable to breast-conserving surgery (diameter [ 3 cm,
central) or with risk factors making neoadjuvant chemo-
therapy the preferred treatment (i.e., N2–N3, rapid growth
rate). Inflammatory breast cancers were allowed.
Availability of frozen tumor tissue for molecular studies
was mandatory. Eligible patients had no history of previous
malignancy other than treated in situ carcinoma of the
cervix or non-melanoma skin cancer, no bilateral breast
cancer, and no distant metastasis. The routine diagnostic
work-up included bilateral mammography and ultrasound,
breast MRI, tumor biopsy with frozen sample, chest
X-rays, abdominal ultrasound, bone scan, blood sampling,
and clinical examination. Patients were eligible is Left
Ventricular Ejection Fraction (LVEF) assessed by MUGA
scan or ultrasound was[50%. HER2 status was considered
positive if the immunohistochemistry result was 3?
according to current ASCO criteria. In doubtful cases (2?),
a FISH analysis was performed. HER2 status was centrally
reviewed for all patients and HER2 positivity confirmed by
FISH in all cases. The cut-off used to define hormone
receptor positivity was 10% of stained cells.
All patients were planned to receive epirubicin
(75 mg/m2)–cyclophosphamide (750 mg/m2) intrave-
nously every 3 weeks for four cycles followed by doce-
taxel (100 mg/m2) every 3 weeks for four cycles with or
without trastuzumab (8 mg/kg at first infusion then 6 mg/kg)
every 3 weeks, according to randomization, for HER2-
positive tumor patients and with or without celecoxib
400 mg BID orally for HER2-negative tumor patients.
Surgery (lumpectomy or modified radical mastectomy
associated to axillary clearance) was performed
21–45 days after cycle 8, according to initial and post-
chemotherapy assessment (MRI evaluation was not
mandatory). Conservative surgery was acceptable in the
absence of multifocality provided clear margins were
obtained. Surgery was followed by local and regional
radiotherapy when indicated (in all cases of breast con-
serving surgery and/or in case of nodal involvement).
The administration of adjuvant trastuzumab for a total of
18 three-weekly infusions was mandatory for all HER2-
positive cancer patients, to be started after surgery for
those randomized to control. Indeed, all patients but eight
received it. All patients with hormone receptor-positive
tumors received adjuvant tamoxifen or aromatase inhib-
itors according to their menopausal status and the current
guidelines. Adjuvant chemotherapy according to centers
preferences in patients with residual axillary nodal
involvement (pN?) could be delivered based on 5-flu-
orouracile and vinorelbine combination, concomitantly or
not with radiotherapy (four cycles).
Clinical evaluation of tumor response was performed
before each subsequent cycle, while mammogram, ultra-
sound and eventually MRI were repeated before cycle 5
and immediately before surgery.
Pathologic tumor response (primary tumor and axillary
nodal status) was evaluated according to Chevallier crite-
ria; a pCR was defined by Chevallier grade 1 or 2 criteria
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[29]: no residual invasive carcinoma in the breast and
axillary nodes. All pathological responses were reviewed
by the panel of pathologists blinded to the center and the
treatment arm.
Safety evaluations
Safety evaluation procedures included clinical evaluations
and blood tests initially and before each subsequent che-
motherapy cycle. Patients with HER2-positive tumors had
LVEF evaluation through the same procedure before ini-
tiation of treatment, before cycles 4 and 6, plus before and
after cycle 8 in the group receiving trastuzumab and sub-
sequently every 3 months during adjuvant trastuzumab.
Statistical methods
The main criterion was pathologic tumor response
according to Chevallier grade 1 or 2 [29]. A two-stage
modified Fleming approach was proposed for each treat-
ment groups, allowing stopping the study only in case of
insufficient antitumor efficacy. In both strata, randomiza-
tion was stratified on treating center.
For each group in Stratum A (HER2 negative), the
percentage defined in null hypothesis was 15% and the
expected percentage was 25% (a level of pathologic tumor
response inferior or equal to 15% was considered as
unacceptable leading to its discontinuation, whereas a level
significantly above 15% as acceptable); inclusion of 110
patients by arm was needed to access the acceptable rate of
25% with a power of 90% and with a equal to 9%. Con-
cerning the decisions rules, if 22 pCR or more were
observed, evidence was provided that the strategy has to be
continued. For each group in Stratum B (HER2 positive),
the percentage defined in null hypothesis was 15% and the
expected percentage was 30% (a level of pathologic tumor
response inferior or equal to 15% was considered as
unacceptable, whereas a level significantly above 15% as
acceptable); inclusion of 60 patients by arm was needed to
access the acceptable rate of 30% with a power of 90% and
with a equal to 7%. Concerning the decisions rules, if 14
pCR or more were observed, evidence was provided that
the strategy has to be continued.
An intermediate analysis was to be conducted when half
of the planned patients had been assessed in the groups in
order to stop study arm(s) in case of insufficient efficacy.
The study was not stopped at this stage (results not
showed) and was conducted up to the end.
Differences between categorical variables were ana-
lyzed by v2 tests or Fisher’s exact test. No comparisons
tests were made between the groups within each stratum:
this study was a stratified randomized phase II conducted to
evaluate the primary efficacy of each therapeutic strategy
and not to compare the groups between them because of a
lack of power in such a case.
Secondary end-points were clinical responses at cycles 4
and 8, tolerance, disease-free survival, biomarkers studies,
and analysis of markers predictive for pathological com-
plete response in each group. Translational studies will be
reported elsewhere. Survival data are not yet available. We
therefore report here mature data on the main end-point
(pathological complete response) together with data on
tolerance and prediction of response in both strata.
Analyses were performed using R software 2.5.0 version.
Results
From May 2004 to October 2007, 341 patients were ran-
domized in this trial. One patient was excluded for a major
violation of the protocol and 340 were analyzed in intent to
treat (Fig. 1, flow chart). Patients’ characteristics are
shown in Table 1. Within each stratum, groups were
overall well balanced. Half of patients had T2 while half
had T3–T4 tumors. It is important to highlight that tumors
were large with 14% of T4 including T4d. None of patients
with HER2 positive tumor had grade 1 carcinoma but 59%
had expression of hormonal receptors.
Compliance to treatment was good: only four patients
stopped for toxicity (1.2%), 10 for tumor progression (3%),
and 10 (3%) for various reasons (patient’s decision, pro-
tocol violation, etc.). Altogether 212/220 patients in Stra-
tum A were operated (104/108 in group A1, 108/112 in
group A2), 214 had axillary sampling (106/112 in group
A2); 119/120 patients in Stratum B were operated and all
had axillary clearance. Therefore, 329 patients were
evaluable for pathological response. For both strata
(Table 2), the first step analysis at 110 and 60 patients in
total indicated that the second step was to be conducted;
the second step analysis after the recruitment of twofold the
number of patients was performed until 340 eligible
patients had been analyzed. In the HER2 negative group
complete pathological rates were 11% without celecoxib
versus 13% with celecoxib. According to sequential anal-
ysis and the decisions rules, at the second stage, as the
number of pCR was below 21, the null hypothesis of a pCR
rate with celecoxib B15% could not be rejected. There was
no apparent increase in response rate with the addition of
celecoxib to sequential neoadjuvant chemotherapy.
For the group of patients with HER2 positive tumor, at
the second step, the number of pCR was superior to 14,
the hypothesis of an increased efficacy of the combined
arm trastuzumab ? chemotherapy with pCR rate of 26%
(95% confidence interval 16–37%) was confirmed pro-
viding evidence that this was a strategy to be continued.
pCR rate was 19% (95% confidence interval 9–29%) in
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the chemotherapy alone arm. Grade 1 response (residual
in situ carcinoma of the breast) rate was 7% (4/58) in the
trastuzumab arm and 19% (12/62) in the arm without
trastuzumab.
There were 78 triple negative breast cancers (23%) in
this study (Table 3). This subgroup of patients experienced
the highest pCR rate, 29.5% (95% confidence interval
19.7–40.9%) compared to 11.4% in all the other subgroups
or to 2% in the HER2 negative, hormonal receptors posi-
tive subgroup.
Clinical complete response rates between the four arms
were: 26.9, 23.2, and 22.4%, respectively, in the arms
without trastuzumab and 33.9% in the arm with trast-
uzumab and clinical response rates (more than 50% tumor
size reduction) were 77.8, 72.3, 86.2, and 77.4%, respec-
tively. In this population with large tumor, not eligible for
primary breast conservative surgery 50% (170/340) of the
patients had lumpectomy with axillary dissection after
neoadjuvant chemotherapy avoiding mastectomy. There
was no suggestion of difference according to HER2 status
and or therapeutic arm (Table 1).
There was no treatment-related death and no Sudden
Unexpected Serious Adverse Event. Use of celecoxib in
randomization in Stratum 1 (HER2 negative tumor
patients) for a new patient was suspended by AFFSAPS
(National French Health authorities) from December 2004
to September 2005 as part of the European assessment of
cardiac side effects of coxib, and was thereafter authorized
with revision of the informed consent form. Tolerance
according to treatment arm is shown in Table 4.
Five (4.6%) HER2 negative tumor patients without
celecoxib had five episodes of skin rash compared to seven
receiving celecoxib who had nine episodes of skin rash.
There was no obvious difference for other toxicities as
shown in Table 2. Reduction of LEVF between 10 and 20%
but with an absolute value[50% was observed in 30 (16.3%)
of the evaluated patients. One patient had a reduction of LVEF
below 50% (45%) in the arm receiving trastuzumab (B2).
Pre-Inclusion  
(Stratification) 341 
randomized patients 
HER2 negative : 
220 patients 
randomized 
HER2 positive: 
120 patients 
randomized 
4 cycles of EC +  4 cycles of EC +  
Randomization Randomization
Stratum A1
4 cycles of docetaxel 
N=108 
Stratum A2
4 cycles of docetaxel 
+Celecoxib 
N=112 
Stratum B1
4 cycles of docetaxel
N=58
Stratum B2
4 cycles of docetaxel
+ trastuzumab 
N=62
1 major protocol 
violation 
End of treatment 
Surgery 
Radiotherapy 
Follow-up 
Adjuvant trastuzumab and hormonal treatment if
indicated
Fig. 1 Flow chart of the
REMAGUS 2 trial
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Discussion
With pathological complete response being the primary
endpoint, the addition of celecoxib to standard sequen-
tial epirubicin/cyclophosphamide—docetaxel in HER2
negative patients does not differ from the null hypothesis
(B15% pCR rate). Indeed the group of HER2 positive
tumor patients with trastuzumab added to docetaxel with
26% (95% confidence interval 16–37%) pCR, was the only
one for which the null hypothesis could be eliminated. The
Table 1 Patients characteristics
N (%) HER2- N = 220 HER2? N = 120
Cx- group (108) Cx? group (112) Total Trastu- group (58) Trastu? group (62) Total
Age Median (SD) 47 (9.1) 47 (9.3) 47 46.5 (8.8) 47 (9.3) 47
Tumor size T2 55 (51%) 65 (58%) 120 (55%) 27 (47%) 32 (52%) 59 (49%)
T3 33 (31%) 37 (33%) 70 (32%) 22 (38%) 21 (34%) 43 (36%)
T4 20 (18%) 10 (9%) 30 (13%) 9 (15.5%) 9 (14.5%) 18 (15%)
Clinical nodal status N0 42 (39%) 45 (40%) 87 (40%) 18 (31%) 25 (40%) 43 (36%)
N1 58 (54%) 55 (49%) 113 (51%) 36 (62%) 34 (55%) 70 (58%)
N2–N3 6 (5%) 12 (11%) 18 (8%) 3 (5%) 3 (5%) 6 (5%)
NA 2 (2%) 0 (0%) 2 (1%) 1 (2%) 0 (0%) 1 (1%)
Tumor grade Grade 1 13 (12%) 7 (6%) 20 (9%) 0 (0%) 0 (0%) 0 (0%)
Grade 2 41 (38%) 56 (50%) 97 (44%) 22 (38%) 25 (40%) 47 (39%)
Grade 3 49 (45%) 47 (42%) 96 (44%) 32 (55%) 35 (56%) 67 (56%)
Grade NA 5 (5%) 2 (2%) 7 (3%) 4 (7%) 2 (3%) 6 (5%)
Hormonal status ER?ve 73 (68%) 67 (60%) 140 (64%) 35 (60%) 32 (52%) 67 (56%)
PR?ve 52 (48%) 46 (41%) 98 (45%) 21 (36%) 20 (32%) 41 (34%)
NA 1 (0.9%) 2 (2%) 3 (1%) 0 (0%) 1 (2%) 1 (1%)
ER and PR- 34 (32%) 44 (39%) 78 (35%) 21 (36%) 28 (45%) 49 (41%)
Surgery Lumpectomy 58 (54%) 56 (50%) 114 (52%) 27 (47%) 29 (47%) 56 (47%)
Mastectomy 46 (43%) 52 (46%) 98 (45%) 30 (53%) 33 (53%) 63 (52%)
No surgery 4 (4%) 4 (4%) 8 (4%) 1 (2%) 0 (0%) 1 (1%)
Radiotherapy Yes 101 (99%) 100 (95%) 201 (97%) 51 (94%) 57 (92%) 108 (93%)
No 1 (1%) 5 (5%) 6 (3%) 3 (6%) 5 (8%) 8 (7%)
Missing data 6 7 13 4 0 4
Hormonotherapy Yes 73 (72%) 66 (62%) 139 (67%) 28 (52%) 29 (47.5%) 57 (49.5%)
No 28 (28%) 40 (38%) 68 (33%) 26 (48%) 32 (52.5%) 58 (50.5%)
Missing data 7 6 13 4 1 5
Systemic treatmenta Yes 31 (30%) 30 (28%) 61 (29%) 48 (89%) 59 (95%) 107 (92%)
No 71 (70%) 76 (72%) 147 (71%) 6 (11%) 3 (5%) 9 (8%)
Missing data 6 6 12 4 0 4
a Adjuvant chemotherapy and/or trastuzumab in HER2? patients)
Table 2 Pathological response according to Chevallier criteria
Chevallier classification N (%) HER2- N = 220 HER2? N = 120
Cx- group
N = 108
Cx? group
N = 112
Trastu- group
N = 58
Trastu? group
N = 62
No residual disease and pN0 Grade 1 8 (7%) 11 (10%) 4 (7%) 12 (19%)
Breast CIS and pN0 Grade 2 4 (4%) 3 (3%) 7 (12%) 4 (6.5%)
Residual invasive carcinoma with treatment-induced changes Grade 3 47 (43.5%) 51 (45.5%) 32 (55%) 31 (50%)
Minimally modified residual invasive carcinoma and/or pN? Grade 4 49 (45%) 47 (42%) 15 (26%) 15 (24%)
Complete response pCR (grade 1 ? 2) 12 (11%) 14 (13%) 11 (19%) 16 (25.5%)
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pCR rate for the whole population is in the low range of
reported values with similar sequential anthracyclines
cyclophosphamide then taxanes chemotherapy regimen
[30]. Among the possible explanations there is the fact that
all cases were reviewed by the panel of pathologists with
very strict criteria of pCR definition, using Chevallier
classification including the nodal status. Also, the median
tumor size was large and none of the patients was eligible
for a breast conservative surgery before chemotherapy.
Chemotherapy with celecoxib was not able to demon-
strate a promising pCR rate in our study. There are few
results of anti-COX2 treatment in breast cancer. Further
explorations with hormonal treatment have been reported
without significant improvement in overall or progression
free survival [31–33]. One phase II trial in 42 patients
combined chemotherapy (capecitabine) and celecoxib in
metastatic breast cancer patients showing an increased time
to progression in case of COX2 over-expression [34]. Our
study is the first randomized trial of combination of che-
motherapy and COX2 inhibitor for localized breast cancer.
However, the lower pCR rates in this study may underes-
timate the benefit of celecoxib. Tolerance was good with
no cardiac event and a small trend for more frequent skin
rashes. While this first analysis does not suggest increase
pCR, however, longer follow-up will be necessary to
ascertain reduction in the metastatic rate. As suggested by
Lucci et al., COX2 produced in primary breast cancer cells
may be vital to the initial development of bone marrow
micrometastasis that may subsequently lead to osteolytic
bone metastases in patients with breast cancer, and COX2
inhibitors may be useful in halting this process [16].
The pCR rate in patients increased to 26% (95% confi-
dence interval 16–37%) in patients with HER2 positive
tumor receiving chemotherapy and trastuzumab [23].
Higher response rates from 41 to 60% have been reported
in the MD Anderson, NOAH and GeparQuattro trials [26–
28]. In these three studies, one should notice that trast-
uzumab was given upfront, for a longer period of time and
was administered concurrently with an anthracyclines-
based chemotherapy regimen without so far overrated
Table 3 Pathological response (Grade 1 and 2) according to hor-
monal receptor status and according to treatment arm in the HER2
positive tumor stratum
ER? and/or
PR?
ER- and PR- Total
HER2- 3/142 (2%) 23/78 (29.5%) 24/220 (10.9%)
HER2?
Trastuzumab- 7/37 (20.5%) 4/21 (19%) 11/58 (19%)
Trastuzumab? 7/34 (20.5%) 9/28 (32%) 16/62 (26%)
Total 14/71 (19.7%) 13/49 (26.5%) 27/120 (22.5%)
Table 4 Treatment-related toxicity
Side effects Side effects N(%) during four cycles of EC Side effects N(%) during four cycles docetaxel
HER2- HER2? HER2- HER2?
Cx- group
(N = 108)
Cx? group
(N = 112)
Trastu- group
(N = 58)
Trastu? group
(N = 62)
Cx- group
(N = 108)
Cx? group
(N = 112)
Trastu- group
(N = 58)
Trastu? group
(N=62)
Skin and nails
Grade 1 ? 2 6 (5.6%) 5 (4.50%) 3 (5.10%) 3 (4.8%) 21 (19.40%) 32 (28.6%) 12 (20.7%) 13 (21.0%)
Grade 3 0 (0%) 0 (0%) 1 (1.7%) 0 (0%) 4 (3.7%) 3 (2.7%) 0 (0%) 2 (3.2%)
Grade 4 0 (0%) 1 (0.9%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 2 (3.2%)
Neutropenia
Grade 1 ? 2 31 (28.7%) 30 (26.7%) 12 (20.7%) 22 (35.5%) 14 (13.0%) 7 (6.3%) 6 (10.4%) 5 (8.0%)
Grade 3 31 (28.7%) 36 (32.1%) 16 (27.6%) 16 (25.8%) 18 (16.7%) 18 (16.1%) 9 (15.5%) 9 (14.5%)
Grade 4 24 (22.2%) 28 (25%) 22 (37.9%) 16 (25.8%) 36 (33.3%) 44 (39.3%) 19 (32.8%) 28 (45.2%)
Febrile neutropenia
Grade 3 8 (7.4%) 8 (7.1%) 3 (5.2%) 5 (8.1%) 10 (9.2%) 12 (10.7%) 7 (12.0%) 11 (17.7%)
Fatigue
Grade 1 ? 2 73 (67.3%) 90 (80.4%) 42 (72.5%) 43 (69.4%) 72 (66.7%) 70 (62.6%) 35 (60.4%) 43 (69.3%)
Grade  2 (1.9%) 0 (0%) 2 (3.4%) 0 (0%) 2 (1.9%) 2 (1.8%) 2 (3.4%) 0 (0%)
Mucositis
Grade 1 ? 2 31 (28.7%) 37 (33.1%) 17 (29.3%) 17 (27.4%) 41 (22.2%) 31 (37.9%) 31 (39.6%) 22 (35.5%)
Grade  0 (0%) 1 (0.9%) 0 (0%) 0 (0%) 4 (3.7%) 0 (0%) 4 (6.9%) 2 (3.2%)
Diarrhea
Grade 1 ? 2 8 (7.4%) 13 (11.6%) 7 (12.0%) 6 (9.7%) 27 (25.0%) 28 (25.0%) 16 (27.6%) 12 (19.3%)
Grade  0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (0.9%) 0 (0%) 0 (0%)
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cardiac consequences. However, caution must be advised
regarding the concomitant use of trastuzumab with anth-
racyclines [19]. In our study, one should pay attention to
the absence of cardiac event. Our results with a low
response rate despite trastuzumab addition substantiates a
very early introduction of trastuzumab in the sequence of
the neoadjuvant chemotherapy and of the possible higher
efficacy of the combination with anthracyclines, targeting
also topoisomerase II which can be more often amplified in
HER2 over-expressing tumor .
Interestingly, grade 2 response (residual ductal carci-
noma in situ DCIS only) was reduced in the trastuzumab
receiving arm, 6.5% versus 12% without trastuzumab in the
subgroup of HER2 positive tumor patient. This has to be put
in perspective with the description of higher rate of HER2
over-expression in DCIS around 60% and the possible
impact of trastuzumab on DCIS; clinical trials by the MD
Anderson and the NSABP are ongoing in this setting [35].
Response rate according to hormonal status in HER2
positive tumor patients did not show important variations.
We observed a trend for a higher response rate with the
addition of trastuzumab predominantly in the estrogen
receptor negative subgroup of patients. This is in contra-
diction with Peinteiger et al. [36] reporting a higher pCR rate
in the HR? subgroup with the addition of trastuzumab in
neoadjuvant setting. In our study, patients with triple nega-
tive breast cancer had exquisite sensitivity to the chemo-
therapy regimen with a pCR rate of 30% compared to 2% in
the RH ? HER negative subgroup. Sensitivity of ER nega-
tive breast to neoadjuvant chemotherapy has been previously
reported [30, 37, 38]. Despite fewer available data with triple
negative this phenotype appears to be a strong predictor of
chemosensitivity [39, 40]. The relation of the phenotype with
gene expression profiling, P53 mutational status as suggested
with a dose dense regimen has been reported [41].
Although pCR is an accepted endpoint in neoadjuvant
studies, it does not always correlate to an overall survival
or disease-free survival benefit, e.g., NSABP 27 showed no
improvement in OS/DFS with taxanes despite a doubling in
pCR [30]. Those patients who do not achieve pCR may still
have a good outcome. However, a recent report of Southern
Italy Cooperative Oncology Group (SICOG) randomized
trial 9908 shows that a significant increase in pCR rate after
neoadjuvant chemotherapy for locally advanced breast
cancer can be translated into RFS and OS improvement
after median follow-up of 74 months [42].
Conclusions
There is no evidence of an increase in pCR with the
addition of anti-COX2 treatment to neoadjuvant chemo-
therapy in HER2 negative breast cancer. There is an
increase in pCR with the addition of trastuzumab to neo-
adjuvant CT in HER2 positive tumor bearing patients but
with a lower rate than reported in the literature when
trastuzumab is used concomitantly with anthracyclines.
This could suggest that the interest of an earlier introduc-
tion of trastuzumab with or without anthracyclines in the
neoadjuvant chemotherapy sequence to obtain a higher
response rate. Longer follow-up is mandatory to prove if
the increased pCR rate translates in gain in survival.
Results of the expression microarrays study on all initial
frozen biopsies are awaited in order to predict more
accurately response to treatment.
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